



Pulmonary, Critical Care and Sleep Medicine Grand Rounds

Presented by: Department of Internal Medicine, Section of Pulmonary, Critical Care and Sleep Medicine

HONOR Lecture: Twenty Years of Progress in the Treatment of Non-Small Cell Lung Cancer: Targeted Therapy, Immunotherapy and the Yale SPORE

02/16/2022 3:00 PM – 4:00 PM EST | Online

Despite advances in the treatment of cancer and reductions in smoking rates, lung cancer continues to be one of the leading causes of cancer death worldwide. For this reason, significant efforts have been made to examine the interaction between cancer and the immune system. Over the past decade, a handful of immune-checkpoint inhibitors (nivolumab, pembrolizumab, atezolizumab) have been shown to improve survival when compared to chemotherapy, however, these treatments only respond in a minority of the patients and even these patients acquire resistance to the therapy. Biomarkers are necessary to help identify the treatments that would most likely benefit a patient. PD-L1 as a marker has been shown to be potentially predictive in some circumstances, but is inconsistent. Other markers such as tumor mutational burden, presence of tumor infiltrating lymphocytes are also being investigated for their ability to differentiate responses. Furthermore, combinations of immunotherapy with other agents such as chemotherapy and targeted therapies are being investigated with some already showing synergy (KEYNOTE-189). Master protocols, like LUNGMAP, are efficient trial designs used to quickly and safely investigate new therapies or combinations. This presentation will review the state of cancer immunotherapy and discuss results from key studies. In addition, mechanistic studies to identify predictive markers of response will be discussed along with markers of resistance (both primary and acquired).



Roy S Herbst, MD, PhD

Ensign Professor of Medicine (Medical Oncology)
Professor of Pharmacology Chief of Medical Oncology
Associate Cancer Center Director for Translational Research
Director, Yale Center for Thoracic Cancers Acting
Director, Yale Cancer Center Clinical Trials Office

Host: Lynn Tanoue, MD

Program Goal:

1. Review the latest therapies for NSCLC
2. Discuss lab-to-clinic therapeutic research in NSCLC
3. Provide an overview of the lung cancer research program at YSM and YC

Target Audience: Critical Care Medicine, Sleep Medicine, Pulmonology Medicine

Financial Disclosure Information:

Richard Matthay, MD, Course Director for this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

Deborah Lovejoy, coordinator for this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

Lynn Tanoue, MD, moderator for this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

Roy S Herbst, MD, faculty for this educational activity, has Consulting Fee-AstraZeneca | Consulting Fee-Eli Lilly and Company | Consulting Fee-Genentech, Inc. | Consulting Fee-Merck and Company, Inc. | Consulting Fee-Pfizer, Inc. All of the relevant financial relationships listed for this individual have been mitigated.

Accreditation Statement: Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement: Yale School of Medicine designates this Live Activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

For questions, email deborah.lovejoy@yale.edu; For information to register, email yalepccsm.grandrounds@yale.edu